Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Convertible Debt (2016 - 2025)

Historic Convertible Debt for Ironwood Pharmaceuticals (IRWD) over the last 11 years, with Q1 2025 value amounting to $199.2 million.

  • Ironwood Pharmaceuticals' Convertible Debt rose 34.41% to $199.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $199.2 million, marking a year-over-year increase of 34.41%. This contributed to the annual value of $199.0 million for FY2024, which is 34.24% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Convertible Debt of $199.2 million as of Q1 2025, which was up 34.41% from $199.0 million recorded in Q4 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Convertible Debt peaked at $436.1 million during Q1 2021, and registered a low of $198.0 million during Q2 2023.
  • For the 5-year period, Ironwood Pharmaceuticals' Convertible Debt averaged around $294.3 million, with its median value being $329.2 million (2021).
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Convertible Debt surged by 2014.13% in 2022, and later crashed by 4996.21% in 2024.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Convertible Debt stood at $337.3 million in 2021, then increased by 17.47% to $396.3 million in 2022, then plummeted by 49.95% to $198.3 million in 2023, then grew by 0.34% to $199.0 million in 2024, then grew by 0.09% to $199.2 million in 2025.
  • Its Convertible Debt stands at $199.2 million for Q1 2025, versus $199.0 million for Q4 2024 and $198.8 million for Q3 2024.